CH629204A5 - Verfahren zur herstellung von 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2h-1,2-benzothiazin-1,1-dioxyd. - Google Patents
Verfahren zur herstellung von 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2h-1,2-benzothiazin-1,1-dioxyd. Download PDFInfo
- Publication number
- CH629204A5 CH629204A5 CH166081A CH166081A CH629204A5 CH 629204 A5 CH629204 A5 CH 629204A5 CH 166081 A CH166081 A CH 166081A CH 166081 A CH166081 A CH 166081A CH 629204 A5 CH629204 A5 CH 629204A5
- Authority
- CH
- Switzerland
- Prior art keywords
- methyl
- formula
- compound
- hydroxy
- benzothiazine
- Prior art date
Links
- -1 5-METHYL-3-ISOXAZOLYLCARBAMOYL Chemical class 0.000 title description 12
- 238000004519 manufacturing process Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 7
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 3
- 150000007529 inorganic bases Chemical class 0.000 claims description 3
- 239000008096 xylene Substances 0.000 claims description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 5
- FKPXGNGUVSHWQQ-UHFFFAOYSA-N 5-methyl-1,2-oxazol-3-amine Chemical compound CC1=CC(N)=NO1 FKPXGNGUVSHWQQ-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 150000001340 alkali metals Chemical class 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000020477 pH reduction Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- DXJICGSIRAJIDN-UHFFFAOYSA-N 2-chloro-N-(5-methyl-3-isoxazolyl)acetamide Chemical compound CC1=CC(NC(=O)CCl)=NO1 DXJICGSIRAJIDN-UHFFFAOYSA-N 0.000 description 2
- GHNLJDPNIAIWOQ-UHFFFAOYSA-N 2h-1$l^{6},2-benzothiazine 1,1-dioxide Chemical compound C1=CC=C2S(=O)(=O)NC=CC2=C1 GHNLJDPNIAIWOQ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RHFWLPWDOYJEAL-UHFFFAOYSA-N 1,2-oxazol-3-amine Chemical class NC=1C=CON=1 RHFWLPWDOYJEAL-UHFFFAOYSA-N 0.000 description 1
- CPIFFCMMBZLKDK-UHFFFAOYSA-N 2-methyl-1,1-dioxo-3h-1$l^{6},2-benzothiazin-4-one Chemical compound C1=CC=C2S(=O)(=O)N(C)CC(=O)C2=C1 CPIFFCMMBZLKDK-UHFFFAOYSA-N 0.000 description 1
- RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 1
- JWINJBQCXAHJFH-UHFFFAOYSA-N 2h-1,2-benzothiazine;oxadiazole Chemical class C1=CON=N1.C1=CC=C2C=CNSC2=C1 JWINJBQCXAHJFH-UHFFFAOYSA-N 0.000 description 1
- NBICRQSSKKUVNN-UHFFFAOYSA-N 4-hydroxy-1,1-dioxo-2h-1$l^{6},2-benzothiazine-3-carboxylic acid Chemical class C1=CC=C2S(=O)(=O)NC(C(=O)O)=C(O)C2=C1 NBICRQSSKKUVNN-UHFFFAOYSA-N 0.000 description 1
- CEFGWFXVHFZNQW-UHFFFAOYSA-N 4-hydroxy-n-(1,2-oxazol-3-yl)-1,1-dioxo-2h-1$l^{6},2-benzothiazine-3-carboxamide Chemical class N1S(=O)(=O)C2=CC=CC=C2C(O)=C1C(=O)NC=1C=CON=1 CEFGWFXVHFZNQW-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000012431 aqueous reaction media Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000002973 irritant agent Substances 0.000 description 1
- 150000002545 isoxazoles Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- OCEZJTJAJHRHDA-UHFFFAOYSA-N n-(5-methyl-1,2-oxazol-3-yl)-2-(1,1,3-trioxo-1,2-benzothiazol-2-yl)acetamide Chemical compound O1C(C)=CC(NC(=O)CN2S(C3=CC=CC=C3C2=O)(=O)=O)=N1 OCEZJTJAJHRHDA-UHFFFAOYSA-N 0.000 description 1
- MPWFKSJGIUHZOH-UHFFFAOYSA-N n-chloro-n-(5-methyl-1,2-oxazol-3-yl)acetamide Chemical compound CC(=O)N(Cl)C=1C=C(C)ON=1 MPWFKSJGIUHZOH-UHFFFAOYSA-N 0.000 description 1
- 150000004866 oxadiazoles Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000006462 rearrangement reaction Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- WZWGGYFEOBVNLA-UHFFFAOYSA-N sodium;dihydrate Chemical compound O.O.[Na] WZWGGYFEOBVNLA-UHFFFAOYSA-N 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US05/577,568 US3957772A (en) | 1975-05-21 | 1975-05-21 | Process for the preparation of 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2h-1,2-benzothiazine 1,1-dioxide |
US05/644,986 US4022796A (en) | 1975-05-21 | 1975-12-29 | 2,3-Dihydro-N-(5-methyl-3-isoxazolyl)-3-oxo-1,2-benzothiazole-2-acetamide 1,1-dioxide |
US05/697,595 US4018762A (en) | 1975-05-21 | 1976-06-18 | Process for the preparation of 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2H-1,2-benzothiazine 1,1-dioxide |
Publications (1)
Publication Number | Publication Date |
---|---|
CH629204A5 true CH629204A5 (de) | 1982-04-15 |
Family
ID=27416273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CH166081A CH629204A5 (de) | 1975-05-21 | 1981-03-11 | Verfahren zur herstellung von 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2h-1,2-benzothiazin-1,1-dioxyd. |
Country Status (11)
Country | Link |
---|---|
US (3) | US3957772A (en, 2012) |
JP (4) | JPS51143682A (en, 2012) |
AU (1) | AU511134B2 (en, 2012) |
BE (1) | BE842079A (en, 2012) |
CA (1) | CA1083572A (en, 2012) |
CH (1) | CH629204A5 (en, 2012) |
DE (1) | DE2618999C2 (en, 2012) |
FR (3) | FR2333802A1 (en, 2012) |
GB (3) | GB1492718A (en, 2012) |
LU (1) | LU74936A1 (en, 2012) |
NL (1) | NL7605246A (en, 2012) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3521513A1 (de) * | 1984-12-28 | 1986-07-10 | J. Uriach & Cia. S.A., Barcelona | Verfahren zur herstellung von 4-hydroxy-3-(5-methyl-3-isoxazolocarbamyl) -2-methyl-2h-1,2-benzothiazin-1,1-dioxid |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3957772A (en) * | 1975-05-21 | 1976-05-18 | Warner-Lambert Company | Process for the preparation of 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2h-1,2-benzothiazine 1,1-dioxide |
US4074048A (en) * | 1976-05-10 | 1978-02-14 | Warner-Lambert Company | Process for the preparation of 4-hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxides |
US4082757A (en) * | 1976-12-10 | 1978-04-04 | Warner-Lambert Company | Amides of 4-hydroxy-6H-thieno[2,3-b]thiopyran-5-carboxylic acid-7,7-dioxide |
EP0061882A1 (en) * | 1981-03-27 | 1982-10-06 | Eli Lilly And Company | Process for preparing isoxazol-3-ylcarboxamides |
DE3311165A1 (de) * | 1983-03-26 | 1984-09-27 | Gödecke AG, 1000 Berlin | Feinkristallines isoxicam |
JPS61238785A (ja) * | 1985-04-16 | 1986-10-24 | Taito Pfizer Kk | 1、2―ベンゾチアジン類 |
JP2543498Y2 (ja) * | 1992-05-22 | 1997-08-06 | 日機装株式会社 | キャンドモータポンプ |
KR960022489A (ko) * | 1994-12-30 | 1996-07-18 | 김준웅 | 방사성동위원소 표지화합물로서의 피록시캄 중간체[¹⁴c]의 제조방법 |
RS49867B (sr) * | 1999-12-06 | 2008-08-07 | Ad. Zdravlje, | Postupak za sintezu 4-hidroksi-2h-1,2-benzotiazin-3-karboksamida |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3787324A (en) * | 1971-03-01 | 1974-01-22 | Warner Lambert Co | 4-hydroxy-3-(3-isoxazolocarbamyl)-2h-1,2-benzothiazine 1,dioxides and process for their production |
US3704298A (en) * | 1971-06-22 | 1972-11-28 | Warner Lambert Co | 4-acyloxy-3-(2-isoxazolocarbamyl)-2h-1,2-benzothiazine 1,1-dioxides |
US3821211A (en) * | 1972-03-10 | 1974-06-28 | Warner Lambert Co | Process for the preparation of 4-hydroxy-3-(5-methyl-3-isoxazolycarbamoyl)-2-methyl-2h-1,2-benzothiazine 1,1-dioxide |
US3868367A (en) * | 1974-04-11 | 1975-02-25 | Warner Lambert Co | 4-Hydroxy-3-(5-isoxazolylcarbamoyl)-2H-1,2-benzothiazine 1,1-dioxides |
US3957772A (en) * | 1975-05-21 | 1976-05-18 | Warner-Lambert Company | Process for the preparation of 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2h-1,2-benzothiazine 1,1-dioxide |
US3960856A (en) * | 1975-06-20 | 1976-06-01 | Warner-Lambert Company | Process for the preparation of 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2H-1,2-benzothiazine 1,1-dioxide |
-
1975
- 1975-05-21 US US05/577,568 patent/US3957772A/en not_active Expired - Lifetime
- 1975-12-29 US US05/644,986 patent/US4022796A/en not_active Expired - Lifetime
-
1976
- 1976-04-28 GB GB19078/77A patent/GB1492718A/en not_active Expired
- 1976-04-28 GB GB17245/76A patent/GB1492717A/en not_active Expired
- 1976-04-28 GB GB19079/77A patent/GB1492719A/en not_active Expired
- 1976-04-29 DE DE2618999A patent/DE2618999C2/de not_active Expired
- 1976-05-06 FR FR7613521A patent/FR2333802A1/fr active Granted
- 1976-05-12 LU LU74936A patent/LU74936A1/xx unknown
- 1976-05-17 NL NL7605246A patent/NL7605246A/xx not_active Application Discontinuation
- 1976-05-20 CA CA252,912A patent/CA1083572A/en not_active Expired
- 1976-05-20 AU AU14129/76A patent/AU511134B2/en not_active Expired
- 1976-05-20 JP JP51058501A patent/JPS51143682A/ja active Granted
- 1976-05-21 BE BE167216A patent/BE842079A/xx not_active IP Right Cessation
- 1976-06-18 US US05/697,595 patent/US4018762A/en not_active Expired - Lifetime
- 1976-09-16 FR FR7627804A patent/FR2313387A1/fr active Granted
- 1976-09-16 FR FR7627803A patent/FR2320744A1/fr active Granted
-
1978
- 1978-02-28 JP JP2275478A patent/JPS53105482A/ja active Granted
- 1978-02-28 JP JP2275678A patent/JPS53108969A/ja active Granted
- 1978-02-28 JP JP2275578A patent/JPS53111065A/ja active Granted
-
1981
- 1981-03-11 CH CH166081A patent/CH629204A5/de not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3521513A1 (de) * | 1984-12-28 | 1986-07-10 | J. Uriach & Cia. S.A., Barcelona | Verfahren zur herstellung von 4-hydroxy-3-(5-methyl-3-isoxazolocarbamyl) -2-methyl-2h-1,2-benzothiazin-1,1-dioxid |
Also Published As
Publication number | Publication date |
---|---|
US4022796A (en) | 1977-05-10 |
GB1492719A (en) | 1977-11-23 |
FR2313387A1 (fr) | 1976-12-31 |
JPS53105482A (en) | 1978-09-13 |
GB1492718A (en) | 1977-11-23 |
US3957772A (en) | 1976-05-18 |
BE842079A (fr) | 1976-09-16 |
AU1412976A (en) | 1977-11-24 |
JPS53111065A (en) | 1978-09-28 |
AU511134B2 (en) | 1980-07-31 |
DE2618999A1 (de) | 1976-12-09 |
JPS5421350B2 (en, 2012) | 1979-07-30 |
FR2333802B1 (en, 2012) | 1980-02-08 |
FR2320744A1 (fr) | 1977-03-11 |
CA1083572A (en) | 1980-08-12 |
JPS5421351B2 (en, 2012) | 1979-07-30 |
JPS5420495B2 (en, 2012) | 1979-07-23 |
FR2313387B1 (en, 2012) | 1980-03-14 |
US4018762A (en) | 1977-04-19 |
JPS53108969A (en) | 1978-09-22 |
JPS5421336B2 (en, 2012) | 1979-07-30 |
NL7605246A (nl) | 1976-11-23 |
GB1492717A (en) | 1977-11-23 |
FR2320744B1 (en, 2012) | 1978-12-15 |
JPS51143682A (en) | 1976-12-10 |
FR2333802A1 (fr) | 1977-07-01 |
LU74936A1 (en, 2012) | 1977-01-17 |
DE2618999C2 (de) | 1985-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3033169C2 (de) | 3,4-disubstituierte 1,2,5-thiadiazol-1-oxide und -1,1-dioxide, verfahren zu ihrer herstellung undsie enthaltende pharmazeutische mittel | |
EP0002482B1 (de) | 4-Hydroxy-2H-1,2-benzothiazin-3-carboxamid-1,1-dioxide, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
DE69431042T2 (de) | Pyrazol oder isoxazol substituierte alkylamide als acat inhibitoren | |
DE1595915C3 (de) | Pyrrolidinderivate | |
DE602004012083T2 (de) | Neue Verbindungen, die als Verstärker von Glutamatrezeptoren dienen | |
AT363096B (de) | Verfahren zur herstellung von neuen phthalazinderivaten und deren salzen | |
DE19824175A1 (de) | Amino-azol-Verbindungen | |
DE69222459T2 (de) | Thiazolidindionderivate, ihre Herstellung und Anwendung | |
CH629204A5 (de) | Verfahren zur herstellung von 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2h-1,2-benzothiazin-1,1-dioxyd. | |
DE69102816T2 (de) | Piperdinyloxy- und Chinindidinyloxy- isoxazol- Derivate, ihre Herstellung und ihre therapeutische Verwendung. | |
EP0014847A1 (de) | Pyrazolderivate, diese enthaltende pharmazeutische Zubereitungen und Verfahren zu ihrer Herstellung | |
DE69002384T2 (de) | Heterocyclische Guanidine als 5HT-3-Antagonisten. | |
DE3405727A1 (de) | Isoxazol-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
EP1157015A1 (de) | Polycyclische 2-amino-thiazol systeme, verfahren zu ihrer herstellung und arzneimittel enthaltend diese verbindungen | |
DE2952652A1 (de) | 1,2-dihydro-2-oxonikotinsaeurederivate und diese enthaltende arzneimittel | |
EP0075140B1 (de) | Tricyclische Thiazolyloxamidsäuren und Derivate, Verfahren zu ihrer Herstellung und diese enthaltende therapeutische Mittel | |
DE3808444A1 (de) | Neue derivate des pyridins, verfahren zu ihrer herstellung und die erhaltenen neuen zwischenprodukte, ihre anwendung als arzneimittel und die sie enthaltenden zusammensetzungen | |
DE2717415A1 (de) | Verfahren zur herstellung von phenylpiperazinderivaten, phenylpiperazinderivate und diese enthaltende pharmazeutische zubereitungen | |
DE69317621T2 (de) | Thiazolidin-2,4-dion-Derivate, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen die sie enthalten | |
DE69107874T2 (de) | Imidazolderivate und diese Imidazolderivate als Wirkstoffe enthaltende Antiepileptika. | |
DE3020421A1 (de) | Imidazoazolalkensaeureamide, neue zwischenprodukte zu ihrer herstellung, ihre herstellung und ihre verwendung in arzneimitteln | |
DE2618978A1 (de) | Verfahren zur herstellung von 1- geschweifte klammer auf eckige klammer auf 5-(4-hydroxy-2h-1,2-benzothiazin- 3-yl)-1,2,4-oxadiazol-3-yl eckige klammer zu methyl geschweifte klammer zu -aethanon- s,s-dioxid sowie bei dem verfahren verwendete zwischenprodukte | |
CH629802A5 (en) | Process for the preparation of 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2H-1,2-benzothia zine 1,1-dioxide | |
EP0764637B1 (de) | 2-Cyano-3-mercaptocrotonsäureamide | |
DE1770177A1 (de) | Monoaryl-substituierte Oxazole |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PL | Patent ceased | ||
PL | Patent ceased |